JP2020530989A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020530989A5 JP2020530989A5 JP2020503988A JP2020503988A JP2020530989A5 JP 2020530989 A5 JP2020530989 A5 JP 2020530989A5 JP 2020503988 A JP2020503988 A JP 2020503988A JP 2020503988 A JP2020503988 A JP 2020503988A JP 2020530989 A5 JP2020530989 A5 JP 2020530989A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- amino acid
- cell
- car
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023117421A JP2023134735A (ja) | 2017-07-25 | 2023-07-19 | 強化されたキメラ抗原受容体およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762536934P | 2017-07-25 | 2017-07-25 | |
| US62/536,934 | 2017-07-25 | ||
| PCT/US2018/043779 WO2019023396A1 (en) | 2017-07-25 | 2018-07-25 | ENHANCED CHIMERIC ANTIGENIC RECEPTORS AND USES THEREOF |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117421A Division JP2023134735A (ja) | 2017-07-25 | 2023-07-19 | 強化されたキメラ抗原受容体およびその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020530989A JP2020530989A (ja) | 2020-11-05 |
| JP2020530989A5 true JP2020530989A5 (enExample) | 2021-09-02 |
Family
ID=65040821
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020503988A Withdrawn JP2020530989A (ja) | 2017-07-25 | 2018-07-25 | 強化されたキメラ抗原受容体およびその使用 |
| JP2023117421A Pending JP2023134735A (ja) | 2017-07-25 | 2023-07-19 | 強化されたキメラ抗原受容体およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023117421A Pending JP2023134735A (ja) | 2017-07-25 | 2023-07-19 | 強化されたキメラ抗原受容体およびその使用 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20240336699A1 (enExample) |
| EP (2) | EP4582146A3 (enExample) |
| JP (2) | JP2020530989A (enExample) |
| KR (1) | KR20200032174A (enExample) |
| CN (2) | CN111432823A (enExample) |
| AU (1) | AU2018306307B2 (enExample) |
| CA (1) | CA3070998A1 (enExample) |
| TW (1) | TW201908335A (enExample) |
| WO (1) | WO2019023396A1 (enExample) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20220033848A1 (en) * | 2018-11-19 | 2022-02-03 | Board Of Regents, The University Of Texas System | A modular, polycistronic vector for car and tcr transduction |
| WO2021032783A1 (en) | 2019-08-21 | 2021-02-25 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Methods for detecting, quantifying and monitoring immune-cell mediated cytotoxicity of cell populations comprising immune cells and/or stem cells |
| NL2023924B1 (nl) * | 2019-10-01 | 2021-06-01 | Lely Patent Nv | Meetsysteem voor levensmiddelen |
| CN115461361B (zh) * | 2020-05-08 | 2025-03-14 | 玛希敦大学 | 嵌合抗原受体和携带该受体的经修饰的细胞 |
| KR102297396B1 (ko) * | 2020-07-29 | 2021-09-06 | (주)티카로스 | 면역시냅스를 안정화시키는 키메라 항원 수용체(car) t 세포 |
| CN116981685A (zh) * | 2020-12-03 | 2023-10-31 | 世纪治疗股份有限公司 | 基因工程化细胞及其用途 |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| CN113045658B (zh) | 2020-12-11 | 2021-12-24 | 广州百暨基因科技有限公司 | 抗cll1抗体及其应用 |
| CN113234169B (zh) * | 2020-12-11 | 2022-11-01 | 广州百暨基因科技有限公司 | 靶向cll1嵌合抗原受体及其应用 |
| WO2022174172A1 (en) * | 2021-02-15 | 2022-08-18 | H. Lee Moffitt Cancer Center And Research Institute Inc. | Customized chimeric antigen receptor polypeptides |
| CA3214473A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Compositions and methods for generating alpha-beta t cells from induced pluripotent stem cells |
| CA3210702A1 (en) | 2021-04-07 | 2022-10-13 | Century Therapeutics, Inc. | Gene transfer vectors and methods of engineering cells |
| AU2022252997A1 (en) | 2021-04-07 | 2023-09-28 | Century Therapeutics, Inc. | Compositions and methods for generating gamma-delta t cells from induced pluripotent stem cells |
| US20240189357A1 (en) * | 2021-04-14 | 2024-06-13 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors to target cd5-positive cancers |
| US20230303655A1 (en) * | 2021-10-18 | 2023-09-28 | Kite Pharma, Inc. | Signaling domains for chimeric antigen receptors |
| WO2023129937A1 (en) | 2021-12-29 | 2023-07-06 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd19 / anti-cd22 chimeric antigen receptors, and uses thereof |
| US20250090582A1 (en) | 2022-06-08 | 2025-03-20 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd133 / anti-egfr chimeric antigen receptors, and uses thereof |
| EP4536814A1 (en) | 2022-06-08 | 2025-04-16 | Century Therapeutics, Inc. | Immunoeffector cells derived from induced pluripotent stem cells genetically engineered with membrane bound il12 and uses thereof |
| WO2024102838A1 (en) | 2022-11-09 | 2024-05-16 | Century Therapeutics, Inc. | Engineered interleukin-7 receptors and uses thereof |
| CN120435498A (zh) | 2022-11-10 | 2025-08-05 | 世纪治疗股份有限公司 | 具有抗-nectin4嵌合抗原受体的基因工程化细胞及其用途 |
| EP4720302A1 (en) * | 2023-05-25 | 2026-04-08 | Legend Biotech Ireland Limited | Chimeric antigen receptors and uses thereof |
| WO2025101938A2 (en) | 2023-11-10 | 2025-05-15 | Century Therapeutics, Inc. | Genetically engineered cells having multi-transmembrane domain chimeric antigen receptors utilizing g protein-coupled receptor scaffolds, and uses thereof |
| WO2025106626A1 (en) | 2023-11-15 | 2025-05-22 | Century Therapeutics, Inc. | Genetically engineered cells expressing c-x-c chemokine receptor type 4, and uses thereof |
| WO2025207798A1 (en) | 2024-03-26 | 2025-10-02 | Century Therapeutics, Inc. | Genetically engineered cells having anti-cd123 chimeric antigen receptors, and uses thereof |
| WO2025207795A1 (en) | 2024-03-26 | 2025-10-02 | Juno Therapeutics, Inc. | Genetically engineered cells having anti-cd33 / anti-cd123 chimeric antigen receptors, and uses thereof |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5621083A (en) * | 1991-11-04 | 1997-04-15 | Xoma Corporation | Immunotoxins comprising ribosome-inactivating proteins |
| WO1993011794A1 (en) * | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| JP4733635B2 (ja) | 2003-07-31 | 2011-07-27 | イミューノメディクス、インコーポレイテッド | 抗ｃｄ１９抗体 |
| JP5956342B2 (ja) * | 2009-11-03 | 2016-07-27 | シティ・オブ・ホープＣｉｔｙ ｏｆ Ｈｏｐｅ | 形質導入Ｔ細胞選択のためのトランケート上皮増殖因子レセプタ（ＥＧＦＲｔ） |
| SG10201806573TA (en) * | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| SG11201505896YA (en) * | 2013-02-20 | 2015-09-29 | Novartis Ag | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor |
| EP2997134B1 (en) * | 2013-05-14 | 2020-06-24 | Board of Regents, The University of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| EP3027204B1 (en) * | 2013-07-29 | 2022-01-05 | 2seventy bio, Inc. | Multipartite signaling proteins and uses thereof |
| US20170158749A1 (en) * | 2014-04-23 | 2017-06-08 | Board Of Regents, The University Of Texas System | Chimeric antigen receptors (car) and methods for making and using the same |
| CA2964785A1 (en) * | 2014-11-05 | 2016-05-12 | Board Of Regents, The University Of Texas System | Gene modified immune effector cells and engineered cells for expansion of immune effector cells |
| EP3250602A1 (en) * | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
| MA41962A (fr) * | 2015-04-23 | 2018-02-28 | Baylor College Medicine | Récepteur antigénique chimérique ciblant le cd5 pour une thérapie adoptive à base de cellules t |
| MX2018006789A (es) * | 2015-12-03 | 2019-02-13 | Juno Therapeutics Inc | Receptores quimericos modificados y composiciones y metodos relacionados. |
| US20180371052A1 (en) * | 2015-12-22 | 2018-12-27 | Icell Gene Therapeutics Llc | Chimeric antigen receptors and enhancement of anti-tumor activity |
-
2018
- 2018-07-25 TW TW107125720A patent/TW201908335A/zh unknown
- 2018-07-25 CN CN201880058794.3A patent/CN111432823A/zh active Pending
- 2018-07-25 AU AU2018306307A patent/AU2018306307B2/en active Active
- 2018-07-25 JP JP2020503988A patent/JP2020530989A/ja not_active Withdrawn
- 2018-07-25 CN CN202410061631.8A patent/CN118206655A/zh active Pending
- 2018-07-25 CA CA3070998A patent/CA3070998A1/en active Pending
- 2018-07-25 WO PCT/US2018/043779 patent/WO2019023396A1/en not_active Ceased
- 2018-07-25 EP EP25169707.4A patent/EP4582146A3/en active Pending
- 2018-07-25 EP EP18838056.2A patent/EP3658163A4/en not_active Withdrawn
- 2018-07-25 KR KR1020207005375A patent/KR20200032174A/ko not_active Ceased
-
2023
- 2023-07-19 JP JP2023117421A patent/JP2023134735A/ja active Pending
-
2024
- 2024-06-21 US US18/750,233 patent/US20240336699A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7599205B2 (ja) | 細胞療法のための多様な抗原結合ドメイン、新規プラットフォームおよびその他の強化 | |
| CN112638947B (zh) | 用于治疗实体瘤的嵌合抗原受体细胞 | |
| US20200038443A1 (en) | Multi-function and multi-targeting car system and methods for use thereof | |
| JP2024500847A5 (enExample) | ||
| JP2022548778A5 (enExample) | ||
| CN108138148B (zh) | T细胞的激活和扩增 | |
| EP4400516A1 (en) | Bispecific or-gate chimeric antigen receptor responsive to cd19 and cd20 | |
| CN118546959A (zh) | Cd19定向性嵌合抗原受体及其在免疫疗法中的用途 | |
| CA3090546A1 (en) | Chimeric antigen receptors targeting the tumor microenvironment | |
| JP2020517259A5 (enExample) | ||
| JP2015527070A5 (enExample) | ||
| WO2014165818A2 (en) | Compositions and methods for preventing and treating prostate cancer | |
| JP2021530971A (ja) | 様々な構築物最適化を備えたｔ細胞抗原カプラ | |
| WO2018045034A1 (en) | Chimeric antigen receptors having gitr intracellular domain as co-stimulatory domain | |
| AU2023234457A1 (en) | Anti-mesothelin antibodies and uses thereof | |
| JP2023515055A5 (enExample) | ||
| WO2023201254A1 (en) | T-cell engaging polypeptides and methods of use thereof | |
| AU2025204510A9 (en) | Car library and scFv manufacturing method | |
| EP4665766A2 (en) | Combination therapy comprising multispecific gamma delta tcr antibodies | |
| AU2021267893A1 (en) | Anti-tumor associated antigen antibodies and uses thereof | |
| Fine et al. | Mechanism-driven design of multispecific antibodies for targeted disease treatment | |
| US20210079111A1 (en) | Cd19-cd20 bispecific and dual passway car-t and methods for use thereof | |
| US20250136703A1 (en) | Anti-il13ra2 antibodies and uses thereof | |
| HK40120953A (en) | Anti-mesothelin antibodies and uses thereof | |
| JP2025538424A (ja) | 併用療法の投与レジメン |